Temasek-backed Pavilion Capital backs funding in AI biopharma firm Insilico

Insilico Medicine

Pavilion Capital, a subsidiary of Singapore’s Temasek Holdings, has participated in the latest strategic funding round in US-headquartered artificial intelligence biopharma company Insilico Medicine. The funding amount was not disclosed.

The round was led by Wuxi AppTec’s Corporate Venture Fund and also backed by therapeutics firm Juvenescence, and BOLD Capital Partners, a venture capital fund investing in exponential technologies, Insilico said in a statement.

“The funding is intended to enhance Insilico Medicine’s work in the innovative approaches to the generation of novel molecules using a variety of machine learning and deep learning techniques, as well as to expand a variety of the biomarker discovery initiatives,” the company said.

Insilico Medicine is an AI firm headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea.

It specializes in the application of deep learning for target identification, drug discovery and aging research. The company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging.

“Our mission is to extend healthy longevity through innovative AI solutions for drug discovery and aging research,” the company said on its website.

The lead investor in the funding round, WuXi App Tech is a global pharmaceutical and medical device open-access capability and technology platform company, while Pavilion Capital, an indirect wholly-owned subsidiary of Temasek Holdings, is a Singapore-based investment firm which is focused on private equity investments in North Asia.

“WuXi AppTec and Insilico Medicine share a mutual vision that artificial intelligence and machine learning will optimize the drug discovery process by increasing the probability of success at the pre-clinical level,” said Dr. Ge Li, Chairman of WuXi AppTec Group.